A: Good question. And the answer is “yes.” Drawing upon the insights and recommendations of the experts throughout Money Map Press, Executive Editor Bill Patalon regularly creates special research reports for subscribers.
For instance, in “The Biotech Buyout Binge: Why these three stocks could double your money in the next 12 months,” Bill let his readers in on a way to make huge gains off a “patent cliff” crisis facing large Biopharma firms. One reader, Amy St. George, who played some of the companies featured in the report, wrote in to tell us,
“You were SPOT ON with ALL your biotech buyout recommendations! Keep ’em coming! I am currently holding CLDX at a 233.45% GAIN. And my biggest, PCYC is at 235.22% and COUNTING.”